KEAP1 and neoplasm: In addition, our ongoing biomarker study, in which tumor mutational burden status and mutations in serine/threonine kinase 11 and Kelch-like ECH-associated protein 1 are being studied, is expected to provide further information regarding the clinical benefit or lack of clinical benefit of the @Be regimen.